Antengene to Present Results from Two Late-Stage Studies of Selinexor Signaling Potential Clinical Breakthrough at ASH 2024
Antengene Corporation, a leading global biopharmaceutical company committed to developing and commercializing innovative therapies for cancer patients, announced today that it will present results from two late-stage studies evaluating the efficacy and safety of selinexor, a selective inhibitor of nuclear export (SINE) compound, at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, to be held in Atlanta, Georgia from December 7 to 10, 2024.
Selinexor is a first-in-class, oral, small-molecule inhibitor of nuclear export (SINE) that targets the nuclear export protein XPO1, which plays a critical role in the transport of tumor suppressor proteins and other important molecules out of the nucleus, leading to the inhibition of cell proliferation and the induction of apoptosis. Antengene’s clinical program has generated significant interest and enthusiasm in the medical community due to the potential of selinexor to deliver meaningful clinical benefit for patients with a wide range of hematologic malignancies, including multiple myeloma (MM) and acute myeloid leukemia (AML).
Data Highlights
At ASH 2024, Antengene will unveil data from two pivotal late-stage studies evaluating selinexor:
1. Selinexor in Combination Therapy for Multiple Myeloma (MM):
The study will report on the overall response rate (ORR) and progression-free survival (PFS) observed in patients with relapsed or refractory MM who received selinexor in combination with other therapies. This study has generated considerable anticipation, as previous studies have shown promising results with selinexor demonstrating an ability to overcome drug resistance and potentially improving treatment outcomes in this challenging patient population.
2. Selinexor in Patients with Acute Myeloid Leukemia (AML):
The study will present data on the complete remission (CR) rate, overall survival (OS), and safety profile of selinexor in combination with standard chemotherapy regimens for patients with AML. Selinexor’s potential in AML is particularly significant, given the limited treatment options available for this aggressive disease.
Significance of the ASH Presentations
These data presentations represent critical milestones in Antengene’s efforts to advance the clinical development of selinexor and potentially offer a new treatment option for patients with blood cancers. If the results of the studies are positive, they could solidify selinexor’s position as a game-changer in the treatment of MM and AML.
“We are excited to share the latest results from our clinical trials with selinexor at ASH 2024,” said Dr. [Name of Spokesperson], [Title] at Antengene Corporation. “The data we are presenting reflect our commitment to delivering innovative treatments that can significantly improve the lives of patients with hematologic malignancies.”
About Antengene Corporation
Antengene Corporation is a global biopharmaceutical company committed to developing and commercializing innovative therapies for cancer patients. The company’s focus is on the development and commercialization of innovative oncology drugs, with a particular focus on hematological malignancies. Antengene’s team of experienced professionals is dedicated to advancing the science of oncology to bring breakthrough therapies to patients worldwide.
About Selinexor
Selinexor (brand name: Xpovio) is a first-in-class, oral, small-molecule inhibitor of nuclear export (SINE) that targets the nuclear export protein XPO1. It is currently approved by the U.S. Food and Drug Administration (FDA) and other global regulatory authorities for the treatment of multiple myeloma in certain patients.
The ASH 2024 presentations will offer crucial insights into the potential of selinexor to deliver a significant impact on patient care in the future. Antengene is committed to expanding its research efforts and investigating the full therapeutic potential of this groundbreaking treatment. The world eagerly awaits the data presented at ASH 2024, which could lead to groundbreaking advancements in hematologic malignancy therapy.
Disclaimer
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical fact are forward-looking statements, including, but not limited to, statements about the potential of selinexor to deliver a significant impact on patient care in the future, Antengene’s commitment to expanding its research efforts and investigating the full therapeutic potential of this groundbreaking treatment, and the anticipation for the data presented at ASH 2024. Actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. These forward-looking statements are based on management’s current expectations and beliefs and are subject to a number of risks and uncertainties, many of which are difficult to predict and beyond Antengene’s control. These and other factors could cause actual results to differ materially from those indicated by forward-looking statements. You should not place undue reliance on any forward-looking statements.
